Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021060841 - NOVEL MULTILAYER SUPPOSITORY AGENT

Publication Number WO/2021/060841
Publication Date 01.04.2021
International Application No. PCT/KR2020/012894
International Filing Date 23.09.2020
IPC
A61K 9/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
02Suppositories; Bougies; Bases for suppositories or bougies
A61K 9/24 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
22Sustained or differential release type
24Layered or laminated unitary dosage forms
A61K 9/20 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
A61K 31/555 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
555containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 31/513 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
513having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
CPC
A61K 2300/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
2300Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
A61K 31/513
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
513having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 31/555
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
555containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 47/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen, ; e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
A61K 47/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Applicants
  • 연세대학교 산학협력단 INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY [KR]/[KR]
Inventors
  • 황성주 HWANG, Sung-Joo
  • 백승혁 BAIK, Seung Hyuk
  • 박은정 PARK, Eun Jung
  • 정세현 JEONG, Se Hyeon
  • 신인택 SHIN, Intaek
Agents
  • 파도특허법인(유한) PADO IP LAW PLLC
Priority Data
10-2019-011684823.09.2019KR
Publication Language Korean (KO)
Filing Language Korean (KO)
Designated States
Title
(EN) NOVEL MULTILAYER SUPPOSITORY AGENT
(FR) NOUVEL AGENT DE SUPPOSITOIRE MULTICOUCHE
(KO) 신규한 다층형 좌약 제제
Abstract
(EN)
The present invention relates to a multilayer suppository agent comprising an outer layer containing a first pharmaceutical ingredient and an inner layer containing a second pharmaceutical ingredient, and a composition comprising same for prevention or treatment of colorectal cancer. The present invention reproduces the release order and release interval of composite drugs administered sequentially in combination, for example, FOLFOX, in the same manner. Accordingly, the present invention enables a composite drug systemically administered in combination by intravenous injection to make a topical action specifically on a lesion and thus can be advantageously available as an effective formulation that focuses a pharmaceutical effect on the lesion, reduces side effects, and improves convenience of administration to patients.
(FR)
La présente invention concerne un agent de suppositoire multicouche comprenant une couche externe contenant un premier ingrédient pharmaceutique et une couche interne contenant un second ingrédient pharmaceutique, et une composition comprenant celui-ci pour la prévention ou le traitement du cancer colorectal. La présente invention reproduit l'ordre de libération et l'intervalle de libération de médicaments composites administrés successivement en association, par exemple, FOLFOX, de la même manière. Par conséquent, la présente invention permet à un médicament composite administré de manière systémique en association par injection intraveineuse d'effectuer une action topique spécifiquement sur une lésion et peut ainsi être avantageusement disponible en tant que formulation efficace qui concentre un effet pharmaceutique sur la lésion, réduit les effets secondaires et améliore la commodité d'administration aux patients.
(KO)
본 발명은 제1 약리성분을 포함하는 외층(outer layer) 및 제2 약리성분을 포함하는 내층(inner layer)을 포함하는 다층형(multilayer) 좌약 제제 및 이를 포함하는 대장암의 예방 또는 치료용 조성물에 관한 것이다. 본 발명은 순차적으로 병용 투여되는 복합약물, 예를 들어 폴폭스(FOLFOX)의 방출 순서 및 방출 간격을 동일하게 재현한다. 이에, 본 발명은 정맥주사를 통해 전신으로 병용 투여되는 복합 약물을 병변부 특이적으로 국소 작용시킴으로써 약리효과를 집중시키고 부작용을 감소시키며 환자 투약 편의성을 크게 향상시킨 효율적인 제형으로 유용하게 이용될 수 있다.
Also published as
Latest bibliographic data on file with the International Bureau